Q2 and H1 FY27 revenue and profit decline despite sequential recovery
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.1 pts more than Nifty 100 and 5.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The company reported unaudited Q2 revenue of Rs 86.71 billion, down 1.5 percent year on year. Profit after tax fell 36 percent to Rs 9.25 billion, while the EBITDA margin declined to 20.6 percent from 26.7 percent. H1 revenue fell 3.5 percent to Rs 167.41 billion and profit after tax dropped 52 percent to Rs 13.69 billion.
Revenue, profit and margins fell year on year, which may pressure the stock. The Q2 rebound from Q1 and double-digit base growth offer some support.